



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology
ESPS manuscript NO: 18469
Title: Anticancer effect of adenosine on gastric cancer through diverse signaling pathways
Reviewer's code: 03319170
Reviewer's country: United States
Science editor: Ya-Juan Ma
Date sent for review: 2015-04-22 16:18
Date reviewed: 2015-04-22 21:59

Table with 4 columns: CLASSIFICATION, LANGUAGE EVALUATION, SCIENTIFIC MISCONDUCT, CONCLUSION. It contains checkboxes for various review criteria like 'Grade A: Excellent', 'Duplicate publication', 'Plagiarism', etc.

COMMENTS TO AUTHORS

The paper by Tsuchiya et al provides an interesting rationale about the potential role of adenosine in gastric cancer therapies. Overall, the review is interesting, timely and well written. My only concern stems from the appreciation of the fact that some of the Authors' own work herein reviewed has not yet been published. Some critical references about AMPK activation through signaling via AdorA2B receptor (ENT-independent) by Yang Xia's group (University of Texas, Houston) are missing. The role of AMPK activation in pro-survival antioxidant (FEBS J. 2014 Oct;281(19):4421-38) and autophagic responses (Nature Cell Biology 13, 132-141 (2011); and Cell Death Dis. 2013 Jun 13;4:e664.) should be further discussed. In the light of the mechanisms proposed in the figures, AMPK activating drugs such as metformin should be also encompassed by this review. Other than these minor comments, I have no major concerns. Introduction: "and have high homologous, but otherwise A3 adenosine receptor is fairly different, depending upon species". Please, reword. "Recent topic has highlighted A3 adenosine receptor as a new target for cancer therapy." Please, reword.